Since my last Adamis Pharmaceutical (ADMP) article, the company has reported their first-quarter revenue that revealed the first ever Symjepi revenues. Perhaps the most surprising development was that the company also held an earnings call...perhaps they have been listening? Overall, the company missed their Q1 earnings, which was expected due to Symjepi being restricted to institutions. The earnings call would be classified as restricted due to Sandoz/Novartis (NVS) being the commercial partner and would be responsible for Symjepi launch related questions. This didn't have a positive impact on the share price